Indian court clears decks for review of Glivec case
This article was originally published in Scrip
Executive Summary
The Supreme Court of India has ruled that a new technical member must be appointed to India's Intellectual Property Appellate Board (IPAB) to consider Novartis's appeal against the rejection of its patent for Glivec (imatinib mesylate).